<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations of hyperkalemia in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations of hyperkalemia in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations of hyperkalemia in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David B Mount, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Sterns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John P Forman, MD, MSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 07, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperkalemia is a common clinical problem that is most often due to impaired urinary potassium excretion due to acute or chronic kidney disease and/or disorders or drugs that inhibit the renin-angiotensin-aldosterone axis. Therapy for hyperkalemia due to potassium retention is ultimately aimed at inducing potassium loss [
         <a href="#rid1">
          1-3
         </a>
         ]. In some cases, the primary problem is movement of potassium out of the cells, even though the total body potassium may be reduced. Redistributive hyperkalemia most commonly occurs in uncontrolled hyperglycemia (eg, diabetic ketoacidosis or hyperosmolar hyperglycemic state). (See
         <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Potassium replacement'
         </a>
         .)
        </p>
        <p>
         The clinical manifestations of hyperkalemia will be reviewed here. The causes, diagnosis, treatment, and prevention of hyperkalemia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2377.html" rel="external">
          "Causes and evaluation of hyperkalemia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">
          "Treatment and prevention of hyperkalemia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most serious manifestations of hyperkalemia are muscle weakness or paralysis, cardiac conduction abnormalities, and cardiac arrhythmias [
         <a href="#rid4">
          4
         </a>
         ]. These manifestations usually occur when the serum potassium concentration is
         <strong>
          ≥7.0 mEq/L
         </strong>
         with chronic hyperkalemia or possibly at lower levels with an acute rise in serum potassium. Patients with skeletal muscle or cardiac manifestations typically have one or more of the characteristic ECG abnormalities associated with hyperkalemia.
        </p>
        <p>
         Other manifestations in hyperkalemic patients may be related to the cause of the hyperkalemia, such as polyuria and polydipsia with uncontrolled diabetes.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Severe muscle weakness or paralysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperkalemia can cause ascending muscle weakness that begins with the legs and progresses to the trunk and arms [
         <a href="#rid5">
          5-7
         </a>
         ]. This can progress to flaccid paralysis, mimicking Guillain-Barré syndrome [
         <a href="#rid6">
          6,7
         </a>
         ]. Sphincter tone and cranial nerve function are typically intact, and respiratory muscle weakness is rare [
         <a href="#rid8">
          8
         </a>
         ]. These manifestations resolve with correction of the hyperkalemia.
        </p>
        <p>
         In addition to acquired hyperkalemia, there is a genetic disorder hyperkalemic periodic paralysis that is caused by autosomal dominant mutations in the skeletal muscle cell sodium channel. Patients with this disorder develop myopathic weakness during hyperkalemia induced by increased potassium intake or rest after heavy exercise. (See
         <a class="medical medical_review" href="/z/d/html/5152.html" rel="external">
          "Hyperkalemic periodic paralysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Cardiac manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperkalemia may be associated with electrocardiographic changes that, if present, may suggest the diagnosis before blood test results. Other manifestations include conduction abnormalities and cardiac arrhythmias.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          ECG changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperkalemia may be associated with a variety of changes on the electrocardiogram (ECG). Tall peaked T waves with a shortened QT interval are usually the first findings (
         <a class="graphic graphic_waveform graphicRef80441" href="/z/d/graphic/80441.html" rel="external">
          waveform 1
         </a>
         ). As the hyperkalemia becomes more severe, there is progressive lengthening of the PR interval and QRS duration, the P wave may disappear, and ultimately the QRS widens further to a sine wave pattern. Ventricular standstill with a flat line on the ECG ensues with complete absence of electrical activity. ECG manifestations can evolve rapidly and unpredictably [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         The presence of ECG changes in patients with hyperkalemia indicates an increased risk of adverse events. For example, in one study of 188 patients with serum potassium &gt;6.5 mEq/L, all patients who had an acute adverse cardiac event (ie, symptomatic bradycardia, ventricular tachycardia, ventricular fibrillation, cardiopulmonary resuscitation, and/or death) had a preceding ECG that demonstrated at least one hyperkalemic abnormality [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         The progression and severity of ECG changes do not correlate well with the serum potassium concentration as illustrated by the following observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a review of 90 patients with hyperkalemia (80 percent with a serum potassium below 7.2 mEq/L), the probability of ECG abnormalities increased with increasing serum potassium, but the ECG was insensitive for the diagnosis of hyperkalemia [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another report, the prevalence of ECG changes suggestive of hyperkalemia was independent of severity (43 and 55 percent in patients with a serum potassium less than 6.8 mEq/L and those with higher values, respectively) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rare patients have a normal ECG despite a serum potassium above 9.0 mEq/L [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ECG manifestations are more likely with rapid onset hyperkalemia [
         <a href="#rid14">
          14
         </a>
         ] and the presence of concomitant hypocalcemia, acidemia, and/or hyponatremia [
         <a href="#rid11">
          11,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Given the unreliable sensitivity, serial measurements of the serum potassium concentration should guide therapy in stable patients with hyperkalemia. The ECG cannot be reliably used to monitor the efficacy of hyperkalemia therapy [
         <a href="#rid13">
          13
         </a>
         ]. In addition, peaked T waves alone are not specific for hyperkalemia, being seen in the early phase of acute myocardial infarction and with early repolarization, and some patients with left ventricular hypertrophy (
         <a class="graphic graphic_table graphicRef73040" href="/z/d/graphic/73040.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid16">
          16,17
         </a>
         ].
        </p>
        <p>
         Hyperkalemia can also cause a type I Brugada pattern in the ECG, with a pseudo-right bundle branch block and persistent "coved" ST segment elevation in at least two precordial leads. This "hyperkalemic Brugada sign" occurs in critically ill patients with significant hyperkalemia (serum potassium concentration &gt;7.0 mEq/L), and can be differentiated from genetic Brugada syndrome by an absence of P waves, marked QRS widening, and/or an abnormal QRS axis [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/106759.html" rel="external">
          "Brugada syndrome: Clinical presentation, diagnosis, and evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Conduction abnormalities and arrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperkalemia can lead to a variety of conduction abnormalities and arrhythmias:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conduction abnormalities that may be seen include right bundle branch block, left bundle branch block, bifascicular block, and advanced atrioventricular block [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac arrhythmias associated with hyperkalemia include sinus bradycardia, sinus arrest, slow idioventricular rhythms, ventricular tachycardia, ventricular fibrillation, and asystole [
         <a href="#rid20">
          20-22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3861146462">
         <span class="h3">
          Cardiac death
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperkalemia increases the risk of mortality in multiple patient populations, including patients with and without preexisting cardiovascular disease [
         <a href="#rid23">
          23,24
         </a>
         ], patients with various severities of chronic kidney disease [
         <a href="#rid25">
          25-30
         </a>
         ], and critically ill hospitalized patients [
         <a href="#rid31">
          31,32
         </a>
         ]. Rapid-onset hyperkalemia may be more lethal than hyperkalemia that develops more slowly [
         <a href="#rid4">
          4,14,33
         </a>
         ]. [
         <a href="#rid26">
          26-32
         </a>
         ] The cause of excess mortality in hyperkalemia is likely multifactorial, but clearly arrhythmia plays an important role [
         <a href="#rid4">
          4,34
         </a>
         ].
        </p>
        <p>
         In patients who present to the emergency department with hyperkalemia and in those who develop hyperkalemia in the intensive care unit, early correction of the serum potassium is associated with reduced mortality [
         <a href="#rid4">
          4,31,32,34-36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Reduced urinary acid excretion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperkalemia interferes with renal ammonium (NH4+) excretion, thereby limiting acid excretion and possibly leading to the development of metabolic acidosis [
         <a href="#rid37">
          37-41
         </a>
         ]. This association has been well described in humans as illustrated by the following observations; similar findings have been described in animal models [
         <a href="#rid41">
          41
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two case reports described patients with isolated hyporeninemic hypoaldosteronism and mild to moderate chronic kidney disease who had hyperkalemia, metabolic acidosis, and reduced urinary NH4+ excretion [
         <a href="#rid38">
          38
         </a>
         ]. Correction of the hyperkalemia with a potassium-sodium exchange resin led to resolution of the acidemia and normalization of urinary NH4+ excretion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study in normal men, ingesting a high potassium diet for five days was associated with a significant reduction in both ammonium and net acid excretion [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Correction of hyperkalemia with the potassium binder ZS-9 is associated with an increase in the serum bicarbonate concentration [
         <a href="#rid42">
          42,43
         </a>
         ]. However, in addition to potential indirect effects on renal ammonium excretion, ZS-9 binds intestinal ammonium [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         At least three mechanisms are thought to contribute to the hyperkalemia-induced diminution in ammonium secretion:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An intracellular alkalosis as entry of some of the excess potassium into the cells is associated with hydrogen ion movement out the cells to maintain electroneutrality. The intracellular alkalosis will reduce both ammonium excretion and bicarbonate reabsorption [
         <a href="#rid38">
          38,40,41,45,46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced NH4+ reabsorption in the thick ascending limb of the loop of Henle [
         <a href="#rid41">
          41,47
         </a>
         ]. In normal subjects, NH4+ can substitute for potassium on the Na-K-2Cl cotransporter in the luminal membrane, a process that is essential for medullary recycling of NH4+, which is subsequently secreted into the medullary collecting duct [
         <a href="#rid48">
          48
         </a>
         ]. With hyperkalemia, potassium competes with NH4+ for transport by the Na-K-2Cl cotransporter, resulting in reductions in medullary recycling and NH4+ secretion and the development of metabolic acidosis. Hyperkalemia also reduces expression of the ammonia transporter Rhcg in the inner stripe of the outer medulla of hyperkalemic animals, thereby reducing ammonia transport across the collecting duct [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diminished proximal tubular ammoniagenesis, mediated in part by reduced glutamine deamination [
         <a href="#rid50">
          50
         </a>
         ]. Hyperkalemia reduces expression of the ammonia-generating enzymes phosphate-dependent glutaminase and phosphoenolpyruvate carboxykinase, along with overexpression of the ammonia-recycling enzyme glutamine synthetase [
         <a href="#rid49">
          49
         </a>
         ]; these changes are reversed by normokalemia.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The muscle weakness and cardiac manifestations induced by hyperkalemia are related to impaired neuromuscular transmission [
         <a href="#rid2">
          2,51
         </a>
         ]. The generation of an action potential (called membrane excitability) is related both to the magnitude of the resting membrane potential and to the activation state of membrane sodium channels. Opening of these sodium channels, leading to the passive diffusion of extracellular sodium into the cells, is the primary step in this process.
        </p>
        <p>
         According to the Nernst equation, the resting electrical potential across the cell membrane is related to the ratio of the extracellular to intracellular potassium concentration. An elevation in the extracellular (plasma) potassium concentration decreases this ratio; makes the resting potential less electronegative and partially depolarizing the cell membrane.
        </p>
        <p>
         The less negative resting potential will initially increase membrane excitability since a lesser depolarizing stimulus is required to generate an action potential. However, the later effect is different. Persistent depolarization inactivates sodium channels in the cell membrane, thereby producing a net decrease in membrane excitability that may be manifested clinically by impaired cardiac conduction and/or neuromuscular weakness or paralysis [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Increases in extracellular potassium also affect the repolarization phase of the cardiac action potential via activation of the rapidly activating delayed rectifier potassium channel (I
         <sub>
          Kr
         </sub>
         ). The HERG (human ether-a-go-go-related) gene encodes the pore-forming subunits of I
         <sub>
          Kr
         </sub>
         , which is largely responsible for potassium efflux during phases 2 and 3 of the cardiac action potential [
         <a href="#rid34">
          34
         </a>
         ]. HERG channels are highly sensitive to changes in extracellular potassium, with inhibition in hypokalemia and activation during hyperkalemia [
         <a href="#rid52">
          52,53
         </a>
         ]. This effect of hyperkalemia on repolarization is thought to underlie the "early" signs of hyperkalemia [
         <a href="#rid21">
          21
         </a>
         ], including ST-T segment depression, peaked T waves, and QT interval shortening [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          PATIENT ASSESSMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Careful monitoring of the ECG and muscle strength are indicated to assess the functional consequences of hyperkalemia. Severe muscle weakness and/or marked electrocardiographic changes, including conduction abnormalities and arrhythmias, are potentially life-threatening and require immediate treatment. These manifestations usually occur when the serum potassium concentration is
         <strong>
          ≥7.0 mEq/L
         </strong>
         with chronic hyperkalemia or possibly at lower levels with an acute rise in serum potassium. (See
         <a class="medical medical_review" href="/z/d/html/2120.html" rel="external">
          "ECG tutorial: Miscellaneous diagnoses", section on 'Hyperkalemia'
         </a>
         .)
        </p>
        <p>
         Rapid increases in serum potassium cause more pronounced cardiac toxicity [
         <a href="#rid33">
          33
         </a>
         ], with greater apparent effects on mortality [
         <a href="#rid4">
          4
         </a>
         ]. A careful history should assess the probable cause of the hyperkalemia (eg, tissue breakdown) and the expected rate of change in serum potassium; treatment should be adjusted accordingly [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">
          "Treatment and prevention of hyperkalemia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3771332528">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109733.html" rel="external">
          "Society guideline links: Fluid and electrolyte disorders in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H114633215">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/17129.html" rel="external">
          "Patient education: Hyperkalemia (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14991202">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most serious manifestations of hyperkalemia are ascending muscle weakness or paralysis, cardiac conduction abnormalities, and cardiac arrhythmias. These usually occur when the serum potassium concentration is ≥7.0 mEq/L if hyperkalemia is chronic or lower if hyperkalemia is acute. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrocardiogram (ECG) changes associated with hyperkalemia include tall peaked T waves with a shortened QT interval; progressive lengthening of the PR interval and QRS duration; disappearance of the P wave; and widening of the QRS complex to a sine wave pattern. The progression and severity of ECG changes do not correlate well with the serum potassium concentration. (See
         <a class="local">
          'ECG changes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conduction abnormalities associated with hyperkalemia include right bundle branch block, left bundle branch block, bifascicular block, and advanced atrioventricular block. Cardiac arrhythmias associated with hyperkalemia include sinus bradycardia, sinus arrest, slow idioventricular rhythms, ventricular tachycardia, ventricular fibrillation, and asystole. (See
         <a class="local">
          'Conduction abnormalities and arrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperkalemia may cause metabolic acidosis by interfering with renal ammonium (NH4+) excretion. (See
         <a class="local">
          'Reduced urinary acid excretion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The functional consequences of hyperkalemia are assessed by careful monitoring of the ECG and muscle strength. Severe muscle weakness and/or marked electrocardiographic changes may require immediate treatment. Rapid increases in serum potassium cause more pronounced cardiac toxicity. (See
         <a class="local">
          'Patient assessment'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Mount DB, Zandi-Nejad K. Disorders of potassium balance. In: Brenner and Rector's The Kidney, 11th ed, Brenner BM (Ed), WB Saunders Co, Philadelphia 2020. p.537.
         </li>
         <li class="breakAll">
          Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, Mc-Graw Hill, New York 2001. p.913.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamel KS, Wei C. Controversial issues in the treatment of hyperkalaemia. Nephrol Dial Transplant 2003; 18:2215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montford JR, Linas S. How Dangerous Is Hyperkalemia? J Am Soc Nephrol 2017; 28:3155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           FINCH CA, SAWYER CG, FLYNN JM. Clinical syndrome of potassium intoxication. Am J Med 1946; 1:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evers S, Engelien A, Karsch V, Hund M. Secondary hyperkalaemic paralysis. J Neurol Neurosurg Psychiatry 1998; 64:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BELL H, HAYES WL, VOSBURGH J. HYPERKALEMIC PARALYSIS DUE TO ADRENAL INSUFFICIENCY. Arch Intern Med 1965; 115:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman SJ, Fale AD. Muscular paralysis and ventilatory failure caused by hyperkalaemia. Br J Anaesth 1993; 70:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glober N, Burns BD, Tainter CR. Rapid Electrocardiogram Evolution in a Dialysis Patient. J Emerg Med 2016; 50:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durfey N, Lehnhof B, Bergeson A, et al. Severe Hyperkalemia: Can the Electrocardiogram Risk Stratify for Short-term Adverse Events? West J Emerg Med 2017; 18:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montague BT, Ouellette JR, Buller GK. Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol 2008; 3:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 1998; 158:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szerlip HM, Weiss J, Singer I. Profound hyperkalemia without electrocardiographic manifestations. Am J Kidney Dis 1986; 7:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surawicz B, Chlebus H, Mazzoleni A. Hemodynamic and electrocardiographic effects of hyperpotassemia. Differences in response to slow and rapid increases in concentration of plasma K. Am Heart J 1967; 73:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aslam S, Friedman EA, Ifudu O. Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in haemodialysis patients. Nephrol Dial Transplant 2002; 17:1639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Somers MP, Brady WJ, Perron AD, Mattu A. The prominent T wave: electrocardiographic differential diagnosis. Am J Emerg Med 2002; 20:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnsdorf MF. Electrocardiogram in Hyperkalemia: electrocardiographic pattern of anteroseptal myocardial infarction mimicked by hyperkalemia-induced disturbance of impulse conduction. Arch Intern Med 1976; 136:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Littmann L, Monroe MH, Taylor L 3rd, Brearley WD Jr. The hyperkalemic Brugada sign. J Electrocardiol 2007; 40:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bashour T, Hsu I, Gorfinkel HJ, et al. Atrioventricular and intraventricular conduction in hyperkalemia. Am J Cardiol 1975; 35:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg A. Hyperkalemia: treatment options. Semin Nephrol 1998; 18:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med 2000; 18:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drumheller BC, Tuffy E, Gibney F, et al. Severe bradycardia from severe hyperkalemia: Patient characteristics, outcomes and factors associated with hemodynamic support. Am J Emerg Med 2022; 55:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grodzinsky A, Goyal A, Gosch K, et al. Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction. Am J Med 2016; 129:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horne L, Ashfaq A, MacLachlan S, et al. Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England. BMC Nephrol 2019; 20:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins AJ, Pitt B, Reaven N, et al. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes. Am J Nephrol 2017; 46:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Impact of admission serum potassium on mortality in patients with chronic kidney disease and cardiovascular disease. QJM 2017; 110:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorriz JL, D'Marco L, Pastor-González A, et al. Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalaemia. Nephrol Dial Transplant 2022; 37:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovesdy CP, Matsushita K, Sang Y, et al. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J 2018; 39:1535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunelli SM, Du Mond C, Oestreicher N, et al. Serum Potassium and Short-term Clinical Outcomes Among Hemodialysis Patients: Impact of the Long Interdialytic Interval. Am J Kidney Dis 2017; 70:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovesdy CP, Regidor DL, Mehrotra R, et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol 2007; 2:999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMahon GM, Mendu ML, Gibbons FK, Christopher KB. Association between hyperkalemia at critical care initiation and mortality. Intensive Care Med 2012; 38:1834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouadma L, Mankikian S, Darmon M, et al. Influence of dyskalemia at admission and early dyskalemia correction on survival and cardiac events of critically ill patients. Crit Care 2019; 23:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paice B, Gray JM, McBride D, et al. Hyperkalaemia in patients in hospital. Br Med J (Clin Res Ed) 1983; 286:1189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parham WA, Mehdirad AA, Biermann KM, Fredman CS. Hyperkalemia revisited. Tex Heart Inst J 2006; 33:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer AJ, Thode HC Jr, Peacock WF. Rapid correction of hyperkalemia is associated with reduced mortality in ED patients. Am J Emerg Med 2020; 38:2361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           An JN, Lee JP, Jeon HJ, et al. Severe hyperkalemia requiring hospitalization: predictors of mortality. Crit Care 2012; 16:R225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karet FE. Mechanisms in hyperkalemic renal tubular acidosis. J Am Soc Nephrol 2009; 20:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szylman P, Better OS, Chaimowitz C, Rosler A. Role of hyperkalemia in the metabolic acidosis of isolated hypoaldosteronism. N Engl J Med 1976; 294:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuda O, Nonoguchi H, Tomita K, et al. Primary role of hyperkalemia in the acidosis of hyporeninemic hypoaldosteronism. Nephron 1988; 49:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tannen RL, Wedell E, Moore R. Renal adaptation to a high potassium intake. The role of hydrogen ion. J Clin Invest 1973; 52:2089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DuBose TD Jr, Good DW. Effects of chronic hyperkalemia on renal production and proximal tubule transport of ammonium in rats. Am J Physiol 1991; 260:F680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Francisco A, Rasmussen H, Lavin P, et al. Normalization of serum bicarbonate with sodium zirconium cyclosilicate (ZS-9) in the Phase 3 randomized, double-blind, placebo-controlled HARMONIZE study. Nephrol Dial Transplant 2015; 30:iii6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ash SR, Singh B, Lavin PT, et al. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int 2015; 88:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stavros F, Yang A, Leon A, et al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One 2014; 9:e114686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           FULLER GR, MACLEOD MB, PITTS RF. Influence of administration of potassium salts on the renal tubular reabsorption of bicarbonate. Am J Physiol 1955; 182:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaeger P, Karlmark B, Giebisch G. Ammonium transport in rat cortical tubule: relationship to potassium metabolism. Am J Physiol 1983; 245:F593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DuBose TD Jr, Good DW. Chronic hyperkalemia impairs ammonium transport and accumulation in the inner medulla of the rat. J Clin Invest 1992; 90:1443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Good DW. Ammonium transport by the thick ascending limb of Henle's loop. Annu Rev Physiol 1994; 56:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris AN, Grimm PR, Lee HW, et al. Mechanism of Hyperkalemia-Induced Metabolic Acidosis. J Am Soc Nephrol 2018; 29:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sleeper RS, Belanger P, Lemieux G, Preuss HG. Effects of in vitro potassium on ammoniagenesis in rat and canine kidney tissue. Kidney Int 1982; 21:345.
          </a>
         </li>
         <li class="breakAll">
          Berne RM, Levy MN. Cardiovascular Physiology, 4th ed, Mosby, St. Louis 1981.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo J, Massaeli H, Xu J, et al. Extracellular K+ concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines. J Clin Invest 2009; 119:2745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charytan D, Goldfarb DS. Indications for hospitalization of patients with hyperkalemia. Arch Intern Med 2000; 160:1605.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2342 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Mount DB, Zandi-Nejad K. Disorders of potassium balance. In: Brenner and Rector's The Kidney, 11th ed, Brenner BM (Ed), WB Saunders Co, Philadelphia 2020. p.537.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, Mc-Graw Hill, New York 2001. p.913.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14551344" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Controversial issues in the treatment of hyperkalaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28778861" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : How Dangerous Is Hyperkalemia?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20998217" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Clinical syndrome of potassium intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9489541" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Secondary hyperkalaemic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14272369" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : HYPERKALEMIC PARALYSIS DUE TO ADRENAL INSUFFICIENCY.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8435272" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Muscular paralysis and ventilatory failure caused by hyperkalaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26826768" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Rapid Electrocardiogram Evolution in a Dialysis Patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28874951" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Severe Hyperkalemia: Can the Electrocardiogram Risk Stratify for Short-term Adverse Events?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18235147" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Retrospective review of the frequency of ECG changes in hyperkalemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9570179" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3717152" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Profound hyperkalemia without electrocardiographic manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6024862" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hemodynamic and electrocardiographic effects of hyperpotassemia. Differences in response to slow and rapid increases in concentration of plasma K.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12198216" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11992348" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The prominent T wave: electrocardiographic differential diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/971008" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Electrocardiogram in Hyperkalemia: electrocardiographic pattern of anteroseptal myocardial infarction mimicked by hyperkalemia-induced disturbance of impulse conduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17188975" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The hyperkalemic Brugada sign.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1119378" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Atrioventricular and intraventricular conduction in hyperkalemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9459288" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hyperkalemia: treatment options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11043630" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Electrocardiographic manifestations of hyperkalemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35306438" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Severe bradycardia from severe hyperkalemia: Patient characteristics, outcomes and factors associated with hemodynamic support.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27060233" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30841854" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28866674" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28637264" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Impact of admission serum potassium on mortality in patients with chronic kidney disease and cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33508124" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29554312" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28111027" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Serum Potassium and Short-term Clinical Outcomes Among Hemodialysis Patients: Impact of the Long Interdialytic Interval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17702709" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Serum and dialysate potassium concentrations and survival in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22806439" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Association between hyperkalemia at critical care initiation and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31856891" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Influence of dyskalemia at admission and early dyskalemia correction on survival and cardiac events of critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6404388" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Hyperkalaemia in patients in hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16572868" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Hyperkalemia revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31884025" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Rapid correction of hyperkalemia is associated with reduced mortality in ED patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23171442" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Severe hyperkalemia requiring hospitalization: predictors of mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19193780" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Mechanisms in hyperkalemic renal tubular acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1674" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Role of hyperkalemia in the metabolic acidosis of isolated hypoaldosteronism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3398981" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Primary role of hyperkalemia in the acidosis of hyporeninemic hypoaldosteronism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4737901" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Renal adaptation to a high potassium intake. The role of hydrogen ion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2035655" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Effects of chronic hyperkalemia on renal production and proximal tubule transport of ammonium in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Normalization of serum bicarbonate with sodium zirconium cyclosilicate (ZS-9) in the Phase 3 randomized, double-blind, placebo-controlled HARMONIZE study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25651363" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25531770" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Characterization of structure and function of ZS-9, a K+ selective ion trap.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13248953" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Influence of administration of potassium salts on the renal tubular reabsorption of bicarbonate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6638180" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Ammonium transport in rat cortical tubule: relationship to potassium metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1401077" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Chronic hyperkalemia impairs ammonium transport and accumulation in the inner medulla of the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8010753" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Ammonium transport by the thick ascending limb of Henle's loop.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29483157" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Mechanism of Hyperkalemia-Induced Metabolic Acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6121928" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Effects of in vitro potassium on ammoniagenesis in rat and canine kidney tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6121928" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Effects of in vitro potassium on ammoniagenesis in rat and canine kidney tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19726881" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Extracellular K+ concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7736582" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10847253" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Indications for hospitalization of patients with hyperkalemia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
